Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity

CHICAGO, June 1, 2019 /PRNewswire/ -- Rakuten Medical, a clinical-stage biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, announces positive data results from its Phase 2a study, evaluating the safety and...

from PR Newswire: http://bit.ly/2WD4LFe